U3 Shut Down As Daiichi Sankyo Streamlines R&D
This article was originally published in PharmAsia News
Executive Summary
Some seven and a half years after buying the venture, Daiichi Sankyo is shutting down its German oncology biologics research operation U3 Pharma, although its remaining pipeline assets are being retained internally.